Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

News > Health News

Audio By Carbonatix

1:05 PM on Monday, February 23

The Associated Press

SAN DIEGO--(BUSINESS WIRE)--Feb 23, 2026--

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences:

TD Cowen's 46th Annual Health Care Conference
Fireside Chat: Monday, March 2, 2026 at 11:10 a.m. Eastern Time in Boston, MA

The Citizens Life Sciences Conference
Fireside Chat: Wednesday, March 11, 2026 at 1:05 p.m. Eastern Time in Miami Beach, FL

Live webcasts will be accessible on the company’s website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

About Acadia Pharmaceuticals

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260223587632/en/

CONTACT: Investor Contact:

Acadia Pharmaceuticals Inc.

Al Kildani

(858) 261-2872

[email protected] Pharmaceuticals Inc.

Jessica Tieszen

(858) 261-2950

[email protected]

KEYWORD: MASSACHUSETTS CALIFORNIA FLORIDA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SCIENCE NEUROLOGY BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH MENTAL HEALTH CLINICAL TRIALS

SOURCE: Acadia Pharmaceuticals Inc.